8-K: PetMed Express to Restate Financials Due to Accounting Errors, Preliminary Q3 Results Show Growth

PetMed Express announced preliminary Q3 results with increased sales and gross profit, but will restate past financials due to errors in sales tax and deferred tax asset accounting.

Summary

• PetMed Express has announced preliminary unaudited financial results for the third quarter ended December 31, 2023.
• Net sales are expected to be $65.3 million, an 11% increase compared to $58.9 million in the same quarter of the previous year.
• Gross profit is expected to be $17.9 million, up from $15.2 million in the prior year period, with gross margin improving to 27.4% from 25.9%.
• The company's cash and equivalents are expected to be $49.4 million as of December 31, 2023.
• The company will restate previously issued financial statements from fiscal years 2021, 2022 and 2023 due to errors in accounting for sales tax liabilities and the valuation of a deferred tax asset related to the PetCareRx acquisition.
• The restatement is expected to result in a decrease in general and administrative expenses of $6 million to $8 million for fiscal year 2023 and a corresponding increase in net income for the same period.
• The company expects to record a sales tax liability of between $14 million and $20 million as of March 31, 2020, and between $16 million and $23 million as of March 31, 2023.
• The restatement will also increase goodwill and decrease the deferred tax asset on the balance sheet as at June 30, 2023.
• The company expects a delay in filing its Q3 2024 10-Q and will file a notification of late filing with the SEC.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, accounting errors, and delay in filing the quarterly report. While there are some positive aspects like sales growth, the accounting issues overshadow them.

Positives

• Net sales increased by 11% year-over-year to $65.3 million for the quarter ended December 31, 2023.
• Gross profit increased to $17.9 million, with an improved gross margin of 27.4%.
• Recurring revenue from AutoShip & Save and PetPlus programs grew to 52.2% of total revenue.
• The company's cash balance remains strong at $49.4 million.
• The restatement is not expected to impact the company's fiscal year 2024 revenue, cost of goods sold, or cash.

Negatives

• The company will restate previously issued financial statements due to errors in accounting for sales tax liabilities and the valuation of a deferred tax asset.
• The restatement will require the company to record a sales tax liability of between $14 million and $23 million.
• The company expects to report one or more material weaknesses following the completion of its analysis.
• There will be a delay in the filing of the Quarterly Report on Form 10-Q for the quarter ended December 31, 2023.

Risks

• The restatement of financial statements could lead to a loss of investor confidence.
• The company may face additional scrutiny from regulators due to the accounting errors.
• The company expects to report one or more material weaknesses in its internal controls over financial reporting.
• The final amounts and effects of the required restatements are not yet known and could be different from current estimates.
• The delay in filing the Q3 2024 10-Q could negatively impact the company's reputation.

Future Outlook

The company remains confident in its strategy and ability to drive long-term value despite the restatement. The company is focused on deepening engagement with pet parents and expanding its portfolio of products and services.

Management Comments

• Matt Hulett, CEO and President, stated that the restatement is a matter of tax accounting and will have no impact on the current cash balance.
• Matt Hulett also noted the continued growth of recurring revenue driven by AutoShip & Save and PetPlus programs.
• Christine Chambers, Chief Financial Officer, said that the restatement is not expected to impact day-to-day business operations or strategic priorities.

Industry Context

The pet health industry is experiencing growth, and PetMed Express is positioning itself to capitalize on this trend through its recurring revenue programs and expanded product offerings. However, the accounting errors and restatement could raise concerns among investors and impact the company's competitive standing.

Comparison to Industry Standards

• PetMed Express's 11% year-over-year sales growth is a positive sign, but it is important to compare this to the growth rates of competitors such as Chewy (CHWY) and Zoetis (ZTS).
• The gross margin improvement to 27.4% is a positive development, but it should be benchmarked against industry averages and the margins of similar online pet retailers.
• The restatement of financials due to accounting errors is a significant issue that could negatively impact investor confidence and is not typical of well-managed companies in the sector.
• The delay in filing the quarterly report is also a concern, as timely and accurate financial reporting is a key expectation for publicly traded companies.

Stakeholder Impact

• Shareholders will be impacted by the restatement of financial statements and the potential for a decrease in share price.
• Employees may be impacted by the increased scrutiny and potential changes in internal controls.
• Customers and suppliers are not expected to be directly impacted by the restatement.

Next Steps

• The company will complete the restatement of its affected financial statements.
• The company will file a notification of late filing on Form 12b-25 with the SEC.
• The company will implement measures to enhance processes and controls.
• The company will assess the effect of the restatements on its internal controls over financial reporting and its disclosure controls and procedures.

Key Dates

Keywords

financial restatement, sales tax liability, deferred tax asset, PetCareRx acquisition, unaudited results, net sales, gross profit, recurring revenue, material weakness, accounting errors